Latest Headlines

  1. IV BioHoldings Debuts Liquid Biopsy Portfolio; Partners With P4 Diagnostix To Scale Commercialization Of Non-Invasive Lung, Liver And Breast Diagnostics 9/22/2021

    IV BioHoldings (IVBH) has announced today the public launch of its bio innovation studio, debuting with a portfolio of three home-grown liquid biopsy companies, including LiquidLung, Inc., HepGene, Inc. and Mammogen, Inc. Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.

  2. IHMA Opens Microbiology Reference Laboratory In Shanghai, China To Further Support Global Anti-Infective Product Discovery And Development 9/22/2021

    IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021. This facility will join IHMA locations in the USA, Switzerland and India to allow the company to provide more robust global support for anti-infective product discovery and development.

  3. Cryogenic Storage Of Biological Specimens 9/22/2021

    Ziath, a leading supplier of equipment, software and consumables to simplify your sample management process, offers a range of CryzoTraq tubes designed for high integrity cryogenic storage of biological specimens at temperatures down to -196°C.

  4. Chembio Announces EUA Submission For DPP Respiratory Antigen Panel 9/22/2021

    Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) application to the Food and Drug Administration (FDA) for the company’s DPP Respiratory Antigen Panel test system.

  5. Roche Launches Three Respiratory Test Panels On cobas 6800/8800 Systems In CE Markets To Help Identify Multiple Pathogens With Overlapping Symptoms In Patients 9/22/2021

    The three tests can be run together or individually from a single nasopharyngeal swab specimen. As respiratory viruses circulating within a community can vary depending on seasonality and geography, a flexible testing option based on a syndromic-style panel enables personalised healthcare and helps reduce unnecessary testing.

  6. Premier Medical Laboratory Services Now A Preferred COVID-19 Testing Lab For Kentucky Schools 9/22/2021

    The Kentucky Department for Public Health has selected Premier Medical Laboratory Services (PMLS), a top CLIA and COLA certified laboratory, as a COVID-19 testing provider for K-12 schools throughout the state of Kentucky. As one of the largest labs in the nation, PMLS can process up to 300,000 COVID-19 samples per day and typically provides results in under 24 hours.

  7. New BD Cell Analyzer Includes Spectral Analysis Capabilities 9/22/2021

    BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the launch of a spectral-enabled cell analyzer, expanding current cell analyzer capabilities to at least 34 parameters with live spectral unmixing, enabling researchers to precisely analyze selected single cells from complex samples.

  8. C₂N Opens State-Of-The-Art CLIA Lab In St. Louis As Alzheimer’s Disease Blood Diagnostic Test Bests Others In Independent Comparison Studies Published In JAMA Neurology 9/21/2021

    On World Alzheimer’s Day, Missouri leaders and economic development officials praise C₂N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease.

  9. Co-Diagnostics, Inc. Logix Smart™ ABC Test Authorized For Use In Mexico 9/21/2021

    Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology ("InDRE") after InDRE successfully concluded an independent evaluation of the test's sensitivity and specificity for use as an RT-PCR multiplex test in that market.

  10. GRAIL Receives New York State Approval For Galleri Multi-Cancer Early Detection Blood Test 9/20/2021

    GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced that the New York State Department of Health (NYSDOH) has approved Galleri, GRAIL’s groundbreaking multi-cancer early detection blood test.